JLS Fund: A Neuromedicine Fund
JLS was formed to invest at the healing edge of innovation across the brain tech and mental health ecosystem, including plant-based medicines, psychedelic-inspired neuroplastogens, and enabling tools and infrastructure.
Investments & Advisories
Investments
Enthea
Mental health company dedicated to providing access to safe and affordable psychedelic-assisted therapy, beginning with ketamine therapy.
Parow
Fully integrated, pre-clinical stage biotechnology company developing therapeutics for the accessible treatment of psychiatric diseases
Gilgamesh
Gilgamesh is developing the next generation of central nervous system drugs derived from psychedelics
Diamond therapEutics
Diamond Therapeutics develops psilocybin based medicines while mitigating side effects
Myco systemics
Myco Systemics' mission is to provide systemic scalable myco-cultivation infrastructure to enable producers to meet the demands of the exploding global mushroom market
Tactogen
Tactogen is a public benefit cooperation whose goal is to make transformative medicines safer, more effective, and more accessible
MINDLEAP HEALTH
Mindleap's integration coaches help you to understand and embody the most important parts of your Psychedelic trip, allowing you to create lasting personal transformation.
atai life sciences
ATAI is committed to developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.
universal ibogaine
Universal Ibogaine's mission is to bring proven Ibogaine based clinical treatment protocol to the world and help solve the international opioid crisis
GoodCap
GoodCap is developing effective mushroom-based treatments that open new pathways to a healthier future.
GWELLA
Gwella's focus is on developing transformative consumer brands, products and technologies aimed at elevating people's health and wellbeing.
LUCID NEWS
Lucid News provides informed, honest and transparent journalism that covers the growing integration of psychedelics into society and their broad implications for human wellness.
double blind
.
A digital media company covering psychedelics and all they intersect with, from healthcare disparities to the climate crisis
wESANA
.
A life sciences company whose mission is to treat traumatic brain injury and other mental health ailments using psilocybin and other natural therapies.
AWAKN LIFE SCIENCES
Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction.
Psilera Bioscience
Psilera is reimagining psychoactive natural products as building blocks for the next generation of neurological therapeutics.
Meet the team
Upcoming Events
Psychedelic Royals – The Acid King
Thursday, April 24th. New York, NY
Join us for a fireside chat facilitated by psychedelic researcher and Founder of Hello SciCom, Sarah Rose Siskind, as Pickard reflects on the past and looks ahead—illuminating what’s next for psychedelics, policy, and cultural change.
Register here.
Investing in Psychedelics – Healthcare, Biotech, and Mental Wellness
Thursday, April 24th.
Simeon Schnapper will be speaking at this exclusive webinar, hosted by YPO’s Psychedelic Medicine for Mental Health Group (PMMH), offering insight into where top investors are placing their bets in this evolving space.
Register here.
The NeuroMedicine Revolution: BrainTech, AI & Psychedelic Therapies Rewiring the Future of Wellbeing - Light DAO Salon (SF)
Monday, April 28th. San Francisco, CA
Simeon Schnapper will host a fireside chat at Light Dao's gathering of conscious entrepreneurs and investors. The evening will be filled with connection and deep conversations, forwarding Light Dao's mission to expand collective consciousness and co-create a thriving regenerative future for humanity.
Register here.
2025 One for Justice Summit
April 29-May 2, 2025. Los Angeles, CA
JLS will be attending this annual event that brings our community and justice reform leaders together to learn, get to know one another, and make coordinated, long-term investments to end our cycle of over-criminalization.
Register here.
Federal Summit on Psychedelic Medicine
May 8, 2025. Washington D.C.
Simeon Schnapper will be speaking and moderating at this convening with members of the new administration, policymakers, researchers, leaders, and advocates shaping the future of psychedelic medicine; building bridges from research to regulation.
Register here.
5th Annual Psychedelic Therapeutics and Drug Development Conference,
May 19-20, 2025. San Diego, CA
A premier industry/academic event at the forefront of innovation in mental health and psychedelic science. This year’s program brings together leaders from biotech, academia, investment, and policy to address the challenges and opportunities shaping the future of psychedelic drug development.
Register here.
MAPS – Mystic Seventh Continent Summit
November 17-25, 2025. Miami, FL
Simeon Schnapper will be speaking at this event, a transformative journey to Antarctica, where the pristine beauty of the Earth’s least explored frontier meets cutting-edge advancements in health, well-being, and psychedelic science.
Use discount code "SIMEON" when registering.
Register here.
Press
Gravity with Brett Kauffman
Simeon Schnapper was the guest on this podcast – a free-wheeling discussion about his life and work.
Lucid News
Lindsay Hoover was interviewed for this article on MAPS PBC's milestone drug application filing with the FTC.
Khaner Global
Simeon Schnapper was interviewed by Jen Coleman, CEO of Elevated Experiences, in advance of of his speaking appearance at Khaner Global's Cannabis and Psychedelics Investment conference later this month
Double Blind
Simeon Schnapper was interviewed for this article on the challenges facing the rapidly expanding psychedelics industry
Benzinga
Simeon Schnapper is among the major psychedelics VC & EFT directors who shared valuable insights at the Psychedelics Capital Conference (PCC)
LUCID News
How Awkn is navigating the tough market for investment capital
LUCID News
Psychedelics were the hot topic at the World Economic Forum 2022
LUCID News
How Awkn is navigating the tough market for investment capital
LUCID News
How Awkn is navigating the tough market for investment capital
Toronto Star
He was the Canadian head of the world’s largest pot company. His next big bet? A rare fungus worth thousands a kilogram
Benzinga
Will Psychedelics Continue To Grow In 2021? Jeff Siegel Shares Insights And Strategies As More Companies Go Public
business insider
Investors are pouring millions into startups that are developing magic mushrooms as medications for conditions like depression and PTSD
Business Insider
Meet the top 14 psychedelics startups raising the most cash to develop new ways of treating depression, addiction, and more
Speaking & Panel Appearances
Investments
Light Dao: Light Alliance Summit
Simeon spoke at this event that united entrepreneurs and business people to form a conscious community to benefit humanity''s future.
Psychedelics for Climate Action
Simeon spoke at this event hosted by PFCA, which bridges the psychedelic and climate ecosystems to inspire meaningful climate action.
Transformative Ventures
JLS participated in this family office, philanthropists, and impact investors-only event in NYC.
Global Eagle Partners
Simeon appeared on Golden Eagle Partners’ (GEP) Global Interactive Webinar, a trusted partner for the cannabis and psychedelics industry.
Mangu.TV
Simeon appeared on the Magu.TV podcast, which distributes regeneration, paradigm shifting, conscious expanding media.
Irreverent Health
Simeon appeared on the Irreverent Health podcast – fascinating conversations about "funky health stuff."
Porta Sophia
Simeon spoke on this webinar "Navigating The Psychedelics Patent Landscape," hosted byPorta Sophia | Psychedelic Prior Art Library
NeueHouse
Simeon spoke on a panel with other leaders of the psychedelic renaissance at "Psychedelics – Agents of Change."
Psychedelic Climate Summit
Simeon spoke in this event, hosted by Psychedelics for Climate Action (PSYCA)
Psychedelic Medicine Israel
Simeon was featured in the Salon, "Making the Magic: In Search of Production Innovation to Meet the Challenges of the Psychedelics Supply Chain."
Transformative Impact Summit Africa
Simeon gave a keynote address: "African Psychedelics Can Heal The World's Trauma."
Psychedelic Therapeutic and Drug Development Conference
Simeon presented at this annual gathering in Boston.
Horizons: Perspectives on Psychedelics
JLS attended this annual community event at the New York Academy of Medicine, the longest-running of its kind in the world.
Momentum PBC
JLS attended "The Summit of Breakthrough Therapies for Addictions" in Miami, Florida.
Top Tier Impact
Simeon Schnapper spoke on the online TTI Panel: Psychedelic and Mental Health VC.
Top Tier Impact
Simeon Schnapper spoke on the online TTI Panel: Psychedelic and Mental Health VC.
CAIS
JLS attended the Cayman Alternative Investment Summit (CAIS), which brought together leaders from multiple segments of the alternative investment world.
RESI JPM
Lindsay Hoover moderated the "Mental & Behavioral Health Panel" at Redefining Early Stage Investments' annual in person conference.
The Cannabis & Psychedelics Investment Summit
Simeon Schnapper spoke at Kahner Global's 7th annual summit in New York City.
Wonderland
Microdose Miami 2023
Lindsay Hoover and Simeon Schnapper spoke on a panel at this thought- leadership event, presented by Microdose.
SOCAP23
Lindsay Hoover spoke at SOCAP Global's annual conference on the following panel: "Impact Investment in Psychedelics: exploring new waters in mental health impact."
MIND Foundation
Simeon Schnapper spoke on the Business Track panel at the MIND Foundation's INSIGHT Conference in Berlin.
Chacruna
Simeon Schnapper spoke on the panel, "The Psychedelics Business Landscape: Are Companies Faltering or Failing, And Why?"
MAPS Psychedelic Conference
Leonard Pickard spoke about the underground history of LSD and its "overground future" at MAPS' fourth annual conference on the future of psychedelic medicine.
MAPS Psychedelic Conference
Lindsay Hoover spoke on two panels at MAPS' fourth annual conference on the future of psychedelic medicine.
The Psychedelic Assembly
Simeon Schnapper co-hosted a thought provoking discussion on the intersection of psychedelics, AI, and robotics.
Benzinga
Simeon Schnapper spoke at the Benzinga Psychedelics Capital Conference in Miami Beach, Florida.
Boston Psychedelic Research Group
William Leonard Pickard spoke at a private event
Boston Psychedelic Research Group
William Leonard Pickard spoke at a private event
Boston Psychedelic Research Group
William Leonard Pickard spoke at a private event
PsychedeMIA
William Leonard Pickard spoke at an interdisciplinary symposium at Ohio State University on the future of psychedelic research
Wholecelium
William Leonard Pickard spoke at the first annual "Psychedelic Science and Spirituality Summit" in Stowe, Vermont
Horizons Northwest
William Leonard Pickard spoke at Horizons Northwest's "Perspectives on Psychedelics" conference
Horizons
Lindsay Hoover spoke at Horizons: The Psychedelic Business Forum, the largest and longest-running annual gathering of the psychedelic community in the world
ICPR 2022
Simeon Schnapper spoke on a panel discussing the intersection of psychedelic research, treatments, and investment
PSYCHOACTIVE
Simeon Schnapper on the tensions between philanthropic and for-profit investment, and the challenges and opportunities of this explosive new sector.
European Ibogaine Forum
Political Importance of Ibogaine Development with Rick Doblin, JLS' Simeon Schnapper, and Daniel Callahan
Alchemy
Simeon Schnapper and Lindsay Hoover discuss investing in the psychedelic space and the developing ecosystem of this emerging industry.
Wonderland Miami
William Leonard Pickard presented at a panel entitled: The Pathway to Federal Acceptance
psychedelics today
Lindsay Hoover speaks on Consolidation in the Psychedelics Industry: What to Expect
Cato Institute
William Leonard Pickard and Caleb O. Brown discuss promise and pitfalls in taking psychedelic medicine mainstream.
Benzinga psychedelics capital conference
Lindsay Hoover on differentiating opportunities between private & public companies
REAL VISION
Jeff Siegel on investing in the future of mental healthcare: psychedelics as an asset class
Benzinga Small Cap Conference
Simeon Schnapper moderates a panel on addressing mental health through emerging therapies.
Games for Change Festival
Lindsay Hoover of JLS Fund: Psychedelics as Therapeutics: The Contribution of Game Heuristics
Psyched
Watch Simeon Schnapper on Pysched, the show that explores psychedelics through political, social, and economic perspectives.
Moderated Conferences
INAUGURAL MICRODOSE CONFERENCE
Moderated by Simeon Schnapper
CEO Panel #1: Srinivas Rao MD, PhD- (ATAI) Payton Nyquvest (Numinus), Judy Blumstock (Diamond Therapeutics) Shlomi Raz (Eleusis), Ronan Levy (FieldTrip)
CEO Panel #2: Jackee Stang (Delic), Todd Shapiro (Red Light Holland), Jonathan Sporn MD (Gilgamesh), Martijn Schirp (Synthesis)
The Mushroom: Paul Stamets (Simeon’s hero), Gary Costner (Mycosystemics), David Kurth (Sporing Company), Eric Osborne (MycoMeditations), Dr K Mandrake (Psilocybin Mushroom Bible)
Venture Capital & Funding: Robert Laurie (MAPS), Florian Brand (ATAI), Mark Hazan (Tabula Rasa) Matthew Nordgren (Arcadian Fund), Bek Muslimov (Leafly Tunnel), Richard Skaife (TCF VC)
Know Thyself: Psychedelics & Spirituality
Moderated by Simeon Schnapper
• The State and Future of Psychedelic Therapist Training with Elizabeth M. Nielson, PhD
• MDMA and Transformative Psychedelic Therapy with Dr. Rick Doblin
• MDMA-assisted Psychotherapy: Beyond Symptom Reduction with Dr. Ingmar Gorman
• Healing What Divides Within with Dr. Willa Hall
• PANEL Q&A: MDMA Therapy with Dr. Hall & Dr. Gorman
• MDMA-Assisted Psychotherapy & Social Anxiety Disorder with Dr. Jason Luoma
• MDMA for Couples Therapy Love & Connection Love and connection with Dr. Anne Wagner
• PANEL Q&A: MDMA Therapy with Dr. Luoma & Dr. Wagner
• The Future of MDMA-Assisted Therapy & Availability Dr. Corine de Boer
• Use of Natural Mind-Altering Substances: Cannabis with Dr. Darryl Hudson
• Psychedelics and Depression with Dr. Xiaojue Hu
All proceeds benefit the Tibet House.
Benzinga
Moderator: Simeon Schnapper
Addressing Mental Health Through Emerging Therapies" Panel
Panelists: Dr. Joseph Tucker, CEO, Enveric; Yaron Conforti, CEO, Novamind; Doug Drysdale, CEO, Cybin; Rob Barrow, CEO, MindMed
The National Cannabis Festival
Moderator: Simeon Schnapper
Psychedelics: The Next Frontier for Legalization
Panelists: Mellisa Lavasani, Founder of Plant Medicine Coalition and Proposer of Washington DC’s successful 2020 ballot measure Initiative 81, the Entheogenic Plant and Fungus Policy Act.
Trailblazers: Sedona
May 2022
- Fireside Chat with Simeon Schnapper and Leonard Pickard
- The Investor State of Mind - WTF is happening?- with Michael Gruber
- Invest In The Future Of Medicine - The Psychedelic Investment Opportunity- with Lindsay Hoover
Capital Psychedelic Conference
June 7, 2022
- JLS moderated a panel on alternative medicine and harm reduction featuring government officials and industry experts.
Trailblazers NYC 2022
Moderated by Simeon Schnapper
Revealing The Mind: The Promise + Opportunity of Psychedelics
Panelists: Simeon Schnapper, Sutton King, Hadas Alterman, Liana Gillooly
JLS Podcast: Leonard Pickard
Weekly Updates
Stay up to speed with the world of psychedelics and neuroscience with our weekly updates. Sign up.
Contact
Ready to invest? See if you qualify.
Take Our Qualification SurveyIs your company in the psytech space?
Company Inquiry FormHave questions or want to learn more?
General InquiriesContacts
